Mode
Text Size
Log in / Sign up
Phase 4 N=25 Treatment

Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit

Constipation

Enrolled (actual)
25
Serious AEs
4.0%
Results posted
Jul 2017
Primary outcome: Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Lubiprostone (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Louisville
Primary completion
May 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Presence of Small Intestinal Bacterial Overgrowth
8; 9 0.75
SECONDARY
Small Bowel and Colon Transit Time by SmartPill® Transit Study
SECONDARY
Small Intestinal Bacterial Overgrowth (SIBO)
8; 9 .9

Summary

Patients with constipation often have bloating and abdominal distension. It is unclear if this is related to intestinal bacteria. Hypothesis: treatment for constipation may reduce small bowel and colon bacteria colonization, a change in the balance of stool microorganisms, and improve the symptoms of dyspepsia and constipation.

Eligibility Criteria

Inclusion Criteria: Functional constipation by Rome III criteria

Exclusion Criteria

  • History of esophageal or gastric surgery (including vagotomy, antireflux, and obesity surgery)
  • History of small bowel or colon resection (excluding appendectomy and cholecystectomy)
  • History of gastric outlet, small bowel, or colon obstruction
  • History of surgery for small bowel adhesion lysis
  • History of surgery for gastroparesis
  • Diagnosis of diabetes requiring daily medications
  • Diagnosis of connective tissue d/o (including scleroderma, lupus, mixed connective tissue disorder)
  • Diagnosis of neuromuscular disorder (including multiple sclerosis, Parkinson, muscular dystrophy, dysautonomia, dystonia)
  • Disorders of small bowel pseudo-obstruction or dumping syndrome
  • Untreated or poorly controlled hypothyroidism
  • Taking an opiate medication daily
  • Taking a medication daily that can cause constipation (calcium channel blocker, anticholinergic, iron supplements, etc.)
  • Active cancer being treated
  • History of significant liver, kidney, cardiac disease that may interfere with study compliance
  • Known allergy or side effects to lubiprostone
  • Non-ambulatory patients: bed-ridden, nursing home resident, etc.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00844831). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search